Tokyo, Dec 3, 2012 (JCN) - Kaneka Corporation has confirmed the effect of the reduced form coenzyme Q10 (Ubiquinol) in improving the chronic fatigue syndrome showing long-lasting fatigue or tiredness, with unknown cause. This research was conducted in collaboration with Special Appointment Prof. Yasuyoshi Watanabe of Osaka City University Graduate School of Medicine.
Kaneka presented the results at the 7th conference of the International Coenzyme Q10 Association early last month in Seville, Spain.
Twenty patients - consisting of five males and 15 females, with an average age of 36.8 years old - with chronic fatigue syndrome were supplemented with Ubiquinol (150mg/day) for two months. Fatigue, sleep quality and depression, oxidative stress and anti-oxidative activities and arithmetic tasks were evaluated before and after two months of the supplementation.
Based on the results, depression symptoms, sleep duration and the performance in the arithmetic task were improved after the supplementation, and these improvements were dependent on increases in plasma coenzyme Q10 levels - which are correlated with decreases in plasma oxidative stress. It is noteworthy that decreases in oxidative stress and in energy production are related to the mechanism on chronic heart failure syndrome.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Kaneka Confirms Positive Effect of Q10 Against Fatigue
(Dec 3, 2012)
|
|
|
Kaneka and Belgium's imec Develop Next-Generation Heterojunction Solar Cells
(June 14, 2012)
|
|
|
Kaneka Builds Plant in Malaysia for Production of PI Film
(Apr 21, 2012)
|
|
|
Kaneka to Establish Umbrella Hubs in Asia and the Americas
(Mar 12, 2012)
|
|
|
AGC, ADEKA and Kaneka to Withdraw Investments from Kashima Denkai and Kashima PVC Monomer
(Dec 21, 2011)
|
|
|
Kaneka, MOL and Mitsui Form CPVC JV in India
(Dec 7, 2011)
|
|
|
Kaneka Develops High-efficiency Heterojunction Silicon Solar Cell
(Nov 28, 2011)
|
|
|
Kaneka Sets Up Base in South Korea
(Nov 23, 2011)
|
|
|
Kaneka Trials Production System for 100% Plant Based Biopolymer Product
(May 14, 2011)
|
|
|
Kaneka Confirms the Effects of Reduced CoQ10 on Mental Health and Physical Activity
(May 2, 2011)
|
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Medical news...
|
|
